Practica oto-rhino-laryngologica. Suppl.
Online ISSN : 2185-1557
Print ISSN : 0912-1870
ISSN-L : 0912-1870
Search
Advanced search
OR
Browse
Search
Volume 1996, Issue Supplement87
Displaying 1-1 of 1 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
  • A Comparison of the Efficacy and Safety between Ramatroban (BAY u 3405) and Terfenadine on Perennial Allergic Rhinitis -A Phase M, Randomized, Double-blind, Parallel Group, Comparative Study-
    Shunkich Baba, [in Japanese], [in Japanese], [in Japanese], [in Japane ...
    1996 Volume 1996 Issue Supplement87 Pages 1-32
    Published: October 01, 1996
    Released on J-STAGE: November 27, 2012
    DOIhttps://doi.org/10.5631/jibirinsuppl1986.1996.Supplement87_1
    JOURNAL FREE ACCESS
    Show abstractHide abstract
    The efficacy and safety of ramatroban (BAY u 3405), a thromboxane A2 receptor antagonist, was compared against terfenadine, a H1-blocker, in a randomized, double-blind, parallel group study on patients with perennial allergic rhinitis. One hundred and fifty mg/day of ramatroban was given to patients in Group B, and 120 mg/day of terfenadine was given to Group T patients for 4 weeks. A total of two hundred and three cases were enrolled in this study. Eighty-nine cases in Group B and 79 cases in Group T were valid for the efficacy comparison,95 patients in Group B and 89 in Group T were valid for the safety comparison, and 86 cases in Group B and 75 in Group T were valid for the usefulness comparison.
    In the final overall improvement rate,67.4% of the patients in Group B and 43.0% of those in Group T were evaluated as moderately or markedly improved. This reveals the significant improvement in Group B patients over Group T patients (U-test: p=0.011; Fisher: p=0.002). In the improvement of symptoms, nasal obstruction (U-test: p=0.004; Fisher: p=0.001) and daily discomfort due to nasal symptoms (U-test: p=0.009; Fisher: p=0.007) were significantly improved in Group B as compared to Group T. However, the nasal provocation (house dust) test was better controlled in Group T than in Group B (U-test: p=0.046).
    Subjective or objective adverse drug reactions were observed in 7 episodes in 5 cases (5.3%) from Group B, and 4 episodes in 3 cases (3.4%) from Group T, with no serious events. Abnormal clinical laboratory findings were noted in 9 tests in 5 cases (3.4%) from Group B and in 8 tests in 6 cases (6.7%) from Group T. In the overall safety comparison, there were no significant differences between the two groups; thus the safety of both drugs was equivalent.
    Based on these results, it can be concluded that ramatroban was significantly superior to terfenadine, especially in the improvement of nasal obstruction.
    View full abstract
    Download PDF (7322K)
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top